Published July 1, 2024

Carpmaels & Ransford is pleased to announce the promotion of patent attorneys Daniel Goodman and Paul Kaufman to the partnership effective from 1 July 2024.

Goodman covers a wide range of biotech inventions, including therapeutic antibodies, antisense compounds, transgenic animals, and cell‑based therapies. He has a sizable European prosecution practice and regularly advocates for clients in offensive and defensive EPO opposition proceedings. Recently, Goodman was one of a trio of Carpmaels attorneys that represented Novartis in G1/22, an Enlarged Board of Appeal referral that fundamentally changed how the EPO examines priority rights.

Kaufman specializes in IP for small-molecule pharmaceuticals. He coordinates patent applications at all stages of the product lifecycle and has extensive experience representing clients in multi-party EPO opposition and appeal proceedings. A significant area of Kaufman’s practice is in Supplementary Protection Certificates (SPCs). Given Kaufman’s expertise in this area, he often works in concert with the Dispute Resolution team at Carpmaels to defend SPCs for some of the world’s largest-selling drugs from generic challenge, in UK and European tribunals.

Hugh Goodfellow, Managing Partner at Carpmaels & Ransford and a Partner in the Life Sciences group, said: “Congratulations to Daniel and Paul who are exceptional patent attorneys. They are leaders in their specialisms of biotech and pharmaceuticals, and their promotions further strengthen our offering to healthcare clients. We are pleased to welcome them to the partnership. ”

Goodman and Kaufman both trained at the firm and were promoted to Senior Associate in 2020. Their recent promotions follow last year’s three female Life Sciences partner promotions, marking another exciting expansion of this team. 

Daniel Goodman

Daniel Goodman

Paul Kaufman

Paul Kaufman

You may also like…

Contact us share your movers & shakers news

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!